Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.43 |
| ▸ | ACACA | Q13085 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855769 | 0.81 | POLB (0.41) | HTTL3MBTL1 | |
| SCHEMBL7723692 | 0.79 | ALDH1A1 (0.46) | ACACBACACAHTTL3MBTL1MTNR1A | |
| SCHEMBL28974132 | 0.78 | HTT (0.66) | ACACBACACAHTTL3MBTL1MTNR1A | |
| SCHEMBL19658634 | 0.78 | L3MBTL1 (0.50) | ACACBACACAHTTL3MBTL1 | |
| SCHEMBL17018471 | 0.78 | HTT (0.66) | ACACBACACAHTTL3MBTL1MTNR1A | |
| SCHEMBL3679108 | 0.78 | ACACB (0.43) | ACACBACACAHTTL3MBTL1MTNR1A | |
| SCHEMBL17753762 | 0.78 | L3MBTL1 (0.50) | ACACBACACAHTTL3MBTL1 | |
| SCHEMBL17018541 | 0.77 | HTT (0.42) | ACACBACACAHTTL3MBTL1MTNR1A | |
| SCHEMBL17018544 | 0.77 | HTT (0.42) | ACACBACACAHTTL3MBTL1MTNR1A | |
| SCHEMBL17018474 | 0.77 | ACACB (0.40) | ACACBACACAHTTL3MBTL1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363421-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-20240140951-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-05-02 | — | — | US | disclosed |
| WO-2024017880-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-01-25 | — | — | WO | disclosed |
| US-20230399328-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-12-14 | — | — | US | disclosed |
| EP-4259631-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-10-18 | — | — | EP | disclosed |
| EP-4240742-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-08-31 | — | — | US | disclosed |
| CN-116406267-A | Bicyclic propyl methyl derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-4132650-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-02-15 | — | — | EP | disclosed |
| WO-2023275301-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-01-05 | — | — | WO | disclosed |
| EP-3990451-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-05-04 | — | — | EP | disclosed |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | US | disclosed |
| WO-2020260426-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020260425-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020261141-A1 | IMIDAZOPYRIDINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| EP-3740478-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-11-25 | — | — | EP | disclosed |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | UCB Biopharma SRL (BE) | 2020-05-07 | — | — | US | disclosed |
| EP-3638227-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018229079-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399328-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL23R, IL2 | ACACB 1923/4885ACACA 1960/4885HTT 4201/4885 |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL2, IL23R | ACACB 1337/4885ACACA 1976/4885HTT 2824/4885 |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | IL17A, IL2, IL18 | ACACB 2271/4885ACACA 2187/4885HTT 1982/4885 |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | IL17A, IL2, IL18 | ACACB 2271/4885ACACA 2187/4885HTT 1982/4885 |
| US-20240140951-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | IL17A, IL15, IL2 | ACACB 3386/4885ACACA 3838/4885HTT 3743/4885 |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | ACACB 3562/4885ACACA 3910/4885HTT 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.